FEBS Letters | |
PI 3‐kinase and MAP kinase regulate bradykinin induced prostaglandin E2 release in human pulmonary artery by modulating COX‐2 activity | |
Corbett, L1  Bradbury, D.A1  Knox, A.J1  | |
[1] Division of Respiratory Medicine, University of Nottingham, City Hospital, Hucknall Road, Nottingham NG5 1PB, UK | |
关键词: Bradykinin; Cyclooxygenase; Prostaglandin E2; Phosphoinositide 3-kinase; Mitogen-activated protein kinase; AA; arachidonic acid; BK; bradykinin; COX; cyclooxygenase; cPLA2; cytosolic phospholipase A2; DMSO; dimethyl sulphoxide; HPASMC; human pulmonary artery smooth muscle cells; LY294002; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one]; MAP kinase; mitogen activated protein kinase; PI 3-K; phosphoinositide 3-kinase; PG; prostaglandin; SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole; | |
DOI : 10.1016/S0014-5793(04)00064-X | |
学科分类:生物化学/生物物理 | |
来源: John Wiley & Sons Ltd. | |
【 摘 要 】
Here we studied the role of phosphoinositide 3-kinase (PI 3-kinase) and mitogen activated protein (MAP) kinase in regulating bradykinin (BK) induced prostaglandin E2 (PGE2) production in human pulmonary artery smooth muscle cells (HPASMC). BK increased PGE2 in a three step process involving phospholipase A2 (PLA2), cyclooxygenase (COX) and PGE synthase (PGES). BK stimulated PGE2 release in cultured HPASMC was inhibited by the PI 3-kinase inhibitor LY294002 and the p38 MAP kinase inhibitor SB202190. The inhibitory mechanism used by LY294002 did not involve cytosolic PLA2 activation or COX-1, COX-2 and PGES protein expression but rather a novel effect on COX enzymatic activity. SB202190 also inhibited COX activity.
【 授权许可】
Unknown
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201912020313873ZK.pdf | 261KB | download |